Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis
Joint Authors
Ma, Sheng-lin
Min-he, Shen
Shan, Feiyu
Sun, Leitao
Ruan, Shanming
Zhang, Leyin
Yu, Jieru
Zhang, Kai
Pang, Xi
Ma, Chenghao
Zhang, Yinan
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-05-13
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Objectives.
Despite the fact that it is widely acknowledged that immune checkpoint inhibitors (ICIs) rely on the presence of immune response to take their antitumor effect, little is known whether there is an influence exerted on the efficacy of ICIs based on patients’ age.
We performed a systematic review and meta-analysis to explore the efficacy of ICIs between younger and older patients.
Materials and Methods.
We searched online database and major conference proceedings for randomized controlled trials (RCTs) published of ICIs and included RCTs that conducted subgroup comparisons of age with available combination of hazard ratios (HRs) and 95% confidence interval (95%CI).
Subsequently, we figured out the pooled HR and 95%CI in younger and older patients with a random-effects model and evaluated the within-study heterogeneity by using subgroup, sensitivity, and meta-regression analysis.
Results and Conclusion.
A total of 12 eligible RCTs included in our study, which reported OS according to patients’ age.
The overall estimated random-effects for HR was 0.75 with 95% CI of 0.65-0.87 in younger arm versus 0.81 with 95% CI of 0.72-0.92 in older arm.
ICIs can improve OS for patients with advanced or metastatic lung cancer when compared to controls, especially for those patients with NSCLC, anti-PD-1/PD-L1 inhibitors, non-squamous, Pembrolizumab or Atezolizumab used as well as subsequent-line setting, and the magnitude of benefit in OS had comparable efficacy in both younger and older arms using a cut-off of 65 yr.
Conversely, we also drew a statically significant conclusion that older patients failed to acquire benefit from ICIs when subdivided with a further cut-off of 75 yr.
American Psychological Association (APA)
Zhang, Leyin& Sun, Leitao& Yu, Jieru& Shan, Feiyu& Zhang, Kai& Pang, Xi…[et al.]. 2019. Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International،Vol. 2019, no. 2019, pp.1-13.
https://search.emarefa.net/detail/BIM-1128892
Modern Language Association (MLA)
Zhang, Leyin…[et al.]. Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International No. 2019 (2019), pp.1-13.
https://search.emarefa.net/detail/BIM-1128892
American Medical Association (AMA)
Zhang, Leyin& Sun, Leitao& Yu, Jieru& Shan, Feiyu& Zhang, Kai& Pang, Xi…[et al.]. Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-13.
https://search.emarefa.net/detail/BIM-1128892
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1128892